These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29741401)

  • 41. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
    Lewczuk P; Popp J; Lelental N; Kölsch H; Maier W; Kornhuber J; Jessen F
    J Alzheimers Dis; 2012; 28(1):119-25. PubMed ID: 21971403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. γH2AX is increased in peripheral blood lymphocytes of Alzheimer's disease patients in the South Australian Neurodegeneration, Nutrition and DNA Damage (SAND) study of aging.
    Siddiqui MS; Francois M; Hecker J; Faunt J; Fenech MF; Leifert WR
    Mutat Res Genet Toxicol Environ Mutagen; 2018; 829-830():6-18. PubMed ID: 29704994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease.
    Lueg G; Gross CC; Lohmann H; Johnen A; Kemmling A; Deppe M; Groger J; Minnerup J; Wiendl H; Meuth SG; Duning T
    Neurobiol Aging; 2015 Jan; 36(1):81-9. PubMed ID: 25277040
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relative Alterations in Blood-Based Levels of Sestrin in Alzheimer's Disease and Mild Cognitive Impairment Patients.
    Rai N; Kumar R; Desai GR; Venugopalan G; Shekhar S; Chatterjee P; Tripathi M; Upadhyay AD; Dwivedi S; Dey AB; Dey S
    J Alzheimers Dis; 2016 Oct; 54(3):1147-1155. PubMed ID: 27567861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dietary pattern and antioxidants in plasma and erythrocyte in patients with mild cognitive impairment from China.
    Yuan L; Liu J; Ma W; Dong L; Wang W; Che R; Xiao R
    Nutrition; 2016 Feb; 32(2):193-8. PubMed ID: 26690564
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. pLG72 levels increase in early phase of Alzheimer's disease but decrease in late phase.
    Lin CH; Chiu CC; Huang CH; Yang HT; Lane HY
    Sci Rep; 2019 Sep; 9(1):13221. PubMed ID: 31520071
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependent test of spatial memory.
    Moodley K; Minati L; Contarino V; Prioni S; Wood R; Cooper R; D'Incerti L; Tagliavini F; Chan D
    Hippocampus; 2015 Aug; 25(8):939-51. PubMed ID: 25605659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The activity of blood serum cholinesterases and neprilysin as potential biomarkers of mild-cognitive impairment and Alzheimer's disease].
    Zhuravin IА; Nalivaeva NN; Kozlova DI; Kochkina EG; Fedorova YB; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):110-117. PubMed ID: 26978503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sirtuin1: a promising serum protein marker for early detection of Alzheimer's disease.
    Kumar R; Chaterjee P; Sharma PK; Singh AK; Gupta A; Gill K; Tripathi M; Dey AB; Dey S
    PLoS One; 2013; 8(4):e61560. PubMed ID: 23613875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?
    Oberacher H; Arnhard K; Linhart C; Diwo A; Marksteiner J; Humpel C
    J Alzheimers Dis; 2017; 57(2):493-504. PubMed ID: 28269764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease.
    Waragai M; Yoshida M; Mizoi M; Saiki R; Kashiwagi K; Takagi K; Arai H; Tashiro J; Hashimoto M; Iwai N; Uemura K; Igarashi K
    J Alzheimers Dis; 2012; 32(1):33-41. PubMed ID: 22751175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging.
    Lin CH; Yang HT; Chiu CC; Lane HY
    Sci Rep; 2017 Nov; 7(1):14849. PubMed ID: 29093468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.